GlassScriptPhysician profile
Erin B Metcalf
NPI 1366752396
$6,604.64
in general payments reported to CMS, 2019-2025
20 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $918 · 2023: $917 · 2024: $2,975 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679 · Travel and Lodging: $1,421 · Gift: $88.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.69 |
| Travel and Lodging | $1,421.26 |
| Gift | $88.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,384.71 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,440.68 | 2021-2025 | Biktarvy, Yeztugo |
| Merck Sharp & Dohme LLC | $450.16 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Scientific Affairs, LLC | $202.07 | 2021-2022 | |
| Insmed, INC. | $198.69 | 2022-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $158.02 | 2021-2023 | Symtuza |
| Shionogi INC | $133.12 | 2022-2025 | Fetroja |
| Janssen Products, LP | $99.00 | 2021 | |
| Abbvie INC. | $87.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $80.05 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Paratek Pharmaceuticals, INC. | $77.30 | 2022-2024 | Nuzyra |
| Pfizer INC. | $64.37 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $44.00 | 2024-2025 | Rebyota |
| Theratechnologies INC. | $41.85 | 2024 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $33.90 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Lilly USA, LLC | $25.19 | 2022 | |
| Recordati_rare_diseases_inc. | $23.71 | 2023 | Sylvant |
| Astellas Pharma US INC | $16.27 | 2024 | Cresemba |
| Vyera Pharmaceuticals, LLC | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Metcalf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.